Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0292 in Chinese Participants With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
NCT07774403Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in bronchiectasis comparing AZD0292 with Placebo (2 arms). Primary endpoint: Annualized rate of exacerbations. Started Jun 2026; status: recruiting.
02
Drugs
AZD-0292
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NCT07774403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07774403.